MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Vesicle monamine transporter(VMAT2)"

  • 2022 International Congress

    Diagnostic value of striatal [18F]-FP-DTBZ PET in Parkinson’s disease

    X. Liu, S. Liu, O. Barret, G. Tamagnan, H. Qiao, T. Song, C. Piu, J. Lu (Beijing, China)

    Objective: To detect the difference of dopaminergic integrity between PDs and healthy controls (HC) using [18F]-FP-DTBZ PET in vivo and to obtain the diagnostic value…
  • MDS Virtual Congress 2021

    Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)

    D. Claassen, R. Ayyagari, V. Garcia-Horton, S. Zhang, S. Leo (Nashville, USA)

    Objective: To identify real-world predictors of persistence to deutetrabenazine in patients with TD or HD. Background: Deutetrabenazine is FDA-approved to treat TD in adults and…
  • MDS Virtual Congress 2021

    Cumulative Real-World Experience with Deutetrabenazine for Huntington’s Disease Chorea at a Single Center of Excellence in the US

    K. Curtis, B. Denson, V. Sung (Birmingham, USA)

    Objective: To summarize clinical experience and outcomes with deutetrabenazine (DTBZ) as a treatment for Huntington’s disease (HD) chorea from the Huntington’s Disease Society of America…
  • MDS Virtual Congress 2021

    Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease

    J. Gamez, M. Calopa, E. Muñoz, A. Ferré, O. Huertas, K. Mcallister, N. Reig, C. Scart-Grès, R. Insa, J. Kulisevsky (Barcelona, Spain)

    Objective: Proof-of-concept phase IIa study assessing bevantolol (SOM3355) efficacy and safety in reducing chorea in Huntington’s disease (HD). Background: Bevantolol hydrochloride, a β1‐adrenoceptor antagonist used…
  • MDS Virtual Congress 2021

    The effects of acute administration of VMAT2 inhibitors on extracellular levels of dopamine, norepinephrine, 5-HT and histamine in the striatum and medial prefrontal cortex

    E. Adler, L. Magid, O. Even-Chen, S. Schmidt, I. Cope, J. Alexander, J. Kehr, A. Orbach (Netanya, Israel)

    Objective: To evaluate the effects of reversible VMAT2 inhibitors (deutetrabenazine, tetrabenazine and valbenazine) on extracellular levels of monoamines and their acidic metabolites in rat striatum…
  • MDS Virtual Congress 2021

    VMAT2 OVEREXPRESSION REDUCES INTRACELLULAR NEUROMELANIN LEVELS AND ATTENUATES PARKINSON-LIKE PATHOLOGY IN NEUROMELANIN-PRODUCING PARKINSONIAN RATS

    J. Compte, M. González, A. Nicolau, T. Cuadros, J. Romero, A. Parent, A. Laguna, M. Vila (Barcelona, Spain)

    Objective: Because neuromelanin derives from the oxidation of free cytosolic dopamine, we hypothesized that enhancing dopamine vesicular encapsulation with vesicular monoamine transporter 2 (VMAT2) will…
  • MDS Virtual Congress 2021

    VMAT2 availability in Parkinson’s Disease with Rapid Eye Movement Sleep Behaviour Disorder

    M. Valli, SS. Cho, C. Uribe, M. Masellis, R. Chen, A. Mihaescu, A. Strafella (Toronto, Canada)

    Objective: To use [11C]DTBZ PET imaging to explore vesicular monoamine transporter 2 (VMAT2) availability in Parkinson’s disease (PD) with and without rapid eye movement sleep…
  • MDS Virtual Congress 2020

    Patient Perspective of Tardive Dyskinesia: Results from a Social Media Listening Study

    L. Lundt, M. Farrar, E. Franey, C. Yonan (San Diego, CA, USA)

    Objective: To use social media listening (SML) to understand the impact of symptoms on patients with assumed/self-reported tardive dyskinesia (TD). Background: TD is a persistent…
  • MDS Virtual Congress 2020

    Real-World Use and Impact of VMAT2 Inhibitors in Patients with Tardive Dyskinesia

    L. Lundt, E. Franey, C. Yonan (San Diego, CA, USA)

    Objective: To describe symptom impact and treatment outcomes in patients prescribed vesicular monoamine 2 (VMAT2) inhibitors for the treatment of tardive dyskinesia (TD). Background: TD,…
  • MDS Virtual Congress 2020

    Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease

    S. Frank, C. Vaughan, D. Stamler, D. Oakes, M. Davis, N. Gross, M. Gordon, J.M Savola, M. Wieman, S. Eberly, E. Kayson, J. Whaley, J. Goldstein, C. Testa (Boston, MA, USA)

    Objective: To evaluate the safety and tolerability of deutetrabenazine >48 mg/d compared to ≤48 mg/d to treat Huntington’s disease (HD)–associated chorea in ARC-HD. Background: In…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley